title: Acute aphasia in multiple sclerosis: A multicenter study of 22 patients.
abstract: Aphasia is usually considered to be rare in multiple sclerosis (MS). To determine the clinical and radiologic characteristics of MS patients with acute aphasia, the authors investigated data from 2,700 patients from three MS centers and found 22 patients with acute aphasia (0.81%). Aphasia was the first clinical manifestation of MS in eight patients (36%). Brain MRI showed giant plaques in eight cases (40%). A full recovery was observed in 14 patients (64%). Furthermore, acute aphasia did not appear to be a criterion for poor prognosis.
authors.affiliation: Department of Neurology, University of Lille, University of Besançon, Lille Cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Lacour
authors.forename: J
authors.initials: J
authors.lastname: De Seze
authors.forename: E
authors.initials: E
authors.lastname: Revenco
authors.forename: C
authors.initials: C
authors.lastname: Lebrun
authors.forename: K
authors.initials: K
authors.lastname: Masmoudi
authors.forename: E
authors.initials: E
authors.lastname: Vidry
authors.forename: L
authors.initials: L
authors.lastname: Rumbach
authors.forename: M
authors.initials: M
authors.lastname: Chatel
authors.forename: A
authors.initials: A
authors.lastname: Verier
authors.forename: P
authors.initials: P
authors.lastname: Vermersch
mesh_terms: D000208:Acute Disease; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001037:Aphasia / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology*; D001379:Azathioprine / Q000627:therapeutic use; D001921:Brain / Q000473:pathology; D015331:Cohort Studies; D015897:Comorbidity; D018450:Disease Progression; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy / Q000453:epidemiology*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000453:epidemiology*; D015995:Prevalence; D020127:Recovery of Function
chemical_list: D000893:Anti-Inflammatory Agents; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D016899:Interferon-beta; D001379:Azathioprine; D008775:Methylprednisolone